Navigation Links
Pharmaceutical Market & Biotechnology Industry 2013 Outlook in New Research Reports at ReportsnReports.com
Date:2/8/2013

DALLAS, Feb. 8. 2013 /PRNewswire-iReach/ -- "Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma" released by MP Advisors and available with ReportsnReports.com provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Key Topics Covered

  • Value Based Pricing- Strength of Innovation Vs Fiscal Pressures
  • Major therapy areas to shape up pharma business going forward
  • Europe – Regulatory Pressures and Increasing Pro Generic Stance
  • Will US fall to Pricing Pressures?
  • Emerging Markets and their importance in Growth of Large Cap Pharma
  • Global Pharma -Drugs Losing Patent Protection By 2017
  • Impact of patent expiry in w.r.t. 2012 total revenue thru 2017
  • Global Pharma Research Pipeline (PhII And PhIII)- 2013
  • Global Pharma Milestones in 2013
  • Roche: Breast Cancer Franchise And Actemra To Drive Near Term Growth, And Multiple Blockbusters In Pipeline To Take Care Of Long Term Growth
  • GlaxoSmithKline: Next Generation Bronchodilators, Melanoma, Hiv And Emerging Market To Lead The Way While Regulatory Overhang In Respiratory And EU Pricing Pressure Persist
  • Bristol- Myers Squibb : Pressures To Dominate In The Near Term, Pipeline Will Take Longer To Deliver
  • AstraZeneca: 2013 Will Be A Transition Year And AZN May Have To Take Some Bold Initiatives
  • Eli Lilly: Late Stage Pipeline Fickle And Risky
  • Merck: News-flow from Mega-trial on MRK's cardiology Franchise would reshape Merck's Growth Prospects
  • Novartis: Back on a Growth Trajectory
  • Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers
  • Pfizer: M&A Only Can Drive Further Upside In The Near Term
  • Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About
  • Global Pharma Sector Industry Tables

Profitable Biotech (Mature Biotech) and non-Profitable Biotech companies (Rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012. We expect this trend to continue in the next five year driven by launch of Innovative drugs catering to unmet needs in Alzheimer's, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.

"Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech" sector report provides valuations and an in depth analyses of biotech companies, their launched drug portfolio and promising drug candidates in the pipeline. The report discusses the competitive landscape of the targeted therapy areas and the innovative strategy each company is deploying to create or retain its leadership in the therapy areas. Forecast for major marketed drugs and drugs in the pipeline are included after factoring, competition, and risks from changing regulatory environment which could change the future market dynamics. Risk reward analyses of important upcoming milestones of the companies are included which should help fund managers as well as pharma company management to make critical decisions.

The New Avatar's of Microbes is a growing threat worldwide and the report "Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars" expect "GAINS" for companies focused in the anti-infective therapy class. "Pill vs. Prick"- is gaining popularity as new oral options are entering the market for RA, Psoriasis, MS etc. Pricing and experience of patients and physicians will drive compliance and define market opportunity of these drugs. Orphan disease focus will continue to remain attractive and success of Eteplirsen (PhII, Sarepta) for the treatment of Duchenne muscular dystrophy (DMD) and other antisense, RNAi drugs in the pipeline could see the final maturing of oligonucleotide based drug therapies. This research provides an in depth analyses of biotech companies and their drug pipeline amidst competition and dynamic regulatory environment.

Explore more reports on the Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ and the Biotechnology Industry @ http://www.reportsnreports.com/market-research/biotechnology/.

About Us:

ReportsnReports.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Our repository covers company profiles and SWOT analysis reports of companies in multiple industries as well as industry profiles for geographies across the globe @ http://www.marketreportsonline.com/.



Media Contact: Priyank Tiwari ReportsnReports.com, + 1 888 391 5441, sales@reportsandreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ReportsnReports.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
2. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
3. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
4. Ohr Pharmaceutical to Present at 15th Annual BIO CEO & Investor Conference
5. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
6. Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures
7. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
8. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
9. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
10. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
11. KaloBios Pharmaceuticals Completes Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Our bodies are bombarded daily by environmental and lifestyle factors that can ... to adopt a more healthful diet, but too many people think that food has ... and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees whole-heartedly. ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... nation’s productivity, stability, even security. Most importantly, employees are the single most important ... are American workers so unhappy? , Just under half of American workers are ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... ... , ... Coast Dental Fort Stewart is celebrating its grand opening with an ... Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, ... have the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group ... of their physicians has been invited to be a featured speaker at the Texas ... conference on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine ...
Breaking Medicine News(10 mins):